Johnson & Johnson has a chance to show it’s more than just a rotation winner
Johnson & Johnson shares have showed signs of life ahead of earnings. For the stock to keep running,…
Stock futures today: Live updates
Traders work on the floor of the New York Stock Exchange during morning trading on June 15, 2026…
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Choosing between established healthcare giants often comes down to balancing income needs against growth potential. Both Bristol Myers…
The AI trade cooled and oil sank. A closer look at Wall Street’s volatile week
Wall Street spent the week debating who the biggest winners and losers of the artificial intelligence boom will…
Healthcare stocks have caught fire, sending all 3 of our names to record highs
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just…
We’re trimming a stock into strength, raising our price target
We are selling 50 shares of Cardinal Health at roughly $235. Following the trade, Jim Cramer’s Charitable Trust…
BlackBerry QNX Extends Beyond Autos As Valuation Runs Ahead Of Targets
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…
Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification
CNBC’s Jim Cramer on Tuesday provided investors a handful of beaten-down stocks that he believes could outperform if…
Doctors hail cancer injection that can destroy entire tumors
Doctors are celebrating the “unprecedented” trial results of a cancer treatment that’s managed to eliminate tumors in some…
Investors’ selling Microsoft stock to fund flashier AI picks won’t last forever
Microsoft is getting left behind as investors rotate into hotter artificial intelligence stocks. Jim Cramer says this dynamic…
The money to AI stocks is a problem, and how it can be fixed
We do not have enough money coming into this market. The funds flow only to stocks tied to…
Eli Lilly to acquire cancer drug maker Kelonia in deal worth up to $7B
Eli Lilly will acquire biotech company Kelonia Therapeutics in a deal worth up to $7 billion, the company…